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ABSTRACT
Objective: This study aimed to identify antibiotic susceptibility rates of enterococcal strains, and to compare the high-
level resistance to aminoglycosides (HLAR) in vancomycin-sensitive enterococcal species (VSE) and vancomycin-resis-
tant enterococcal species (VRE). 
Methods: The study included 100 VRE and 100 VSE strains recovered from the samples sent to laboratory from various 
departments of Haydarpaşa Numune Training and Research Hospital. 
Results: All VRE strains were defined as Enterococcus faecium, although of the VSE strains, 53% were identified to be 
as Enterococcus faecalis, 42% E. faecium, 3% Enterococcus durans, and 2% Enterococcus avium. High-level resistance to 
vancomycin (MIC, >256 µg/ml) was determined in all VRE strains and when analyzing MIC values for teicoplanin, five 
strains were found to be moderately susceptible (MIC, 16 µg/ml) and 95 strains were resistant (MIC, >32 µg/ml). Of the 
VRE strains, one was linezolid-resistant (MIC, 12 µg/ml) and the other was intermediately susceptible (MIC, 4 µg/ml) and 
remainders were evaluated to be susceptible (MIC, <2 µg/ml). In VRE strains, high-level gentamicin resistance (HLGR) 
was found to be 83% and high-level streptomycin resistance (HLSR) 89%, association of HLSR with HLGR was 78%. In 
VSE strains, HLGR was found to be 42% and, HLSR 48%, the association of HLSR with HLGR was found to be 36%. HLAR 
in VRE strains was found to be higher as compared with VSE strains (p <0.005). 
Conclusion: Antimicrobial resistance is increasing in enterococci strains. Therefore a follow-up is required resistance 
pattern including both vancomycin resistance and HLAR. J Microbiol Infect Dis 2013; 3(3): 100-103
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Enterokoklarda yüksek düzey aminoglikozid, vankomisin ve linezolid direnci
ÖZET
Amaç: Bu çalışmada, enterokok suşlarının antibiyotik duyarlılık oranlarının saptanması, vankomisin duyarlı enterokok 
(VSE) ve vankomisin dirençli enterokok (VRE) suşlarındaki yüksek düzey aminoglikozid direncinin karşılaştırılması amaç-
landı. 
Yöntemler: Haydarpaşa Numune Eğitim ve Araştırma Hastanesi kliniklerinden gönderilen örneklerden, laboratuvarımız-
da izole edilen 100 adet VRE, 100 adet VSE suşu çalışma kapsamına alındı.
Bulgular: VRE suşlarının tümü Enterococcus faecium olarak tanımlanmış olup, VSE suşlarının ise %53’ü Enterococcus fae-
calis, %42’si E. faecium, %3’ü Enterococcus durans, %2’si Enterococcus avium olarak tespit edildi. VRE suşlarının tümünde 
yüksek düzey vankomisin direnci (MİK, >256 µg/ml) belirlendi, teikoplanin MİK değerleri incelendiğinde beş suş orta 
duyarlı (MİK, 16µg/ml), 95 suş dirençli (MİK, >32 µg/ml) olarak saptandı. VRE suşlarından biri linezolid dirençli (MİK, 12 
µg/ml), biri ise orta duyarlı (MİK, 4 µg/ml) olarak saptandı, diğer suşlar duyarlı (MİK, <2 µg/ml) olarak değerlendirildi. 
VRE suşlarında yüksek düzey gentamisin direnci (YDGD) %83, yüksek düzey streptomisin direnci (YDSD) %89, YDSD 
ve YDGD birlikteliği %78 olarak bulundu. VSE suşlarında YDGD %42, YDSD %48, YDSD ve YDGD birlikteliği %36 olarak 
tespit edilmiştir. VRE’lerde YDAD’nin VSE suşlarına göre yüksek olduğu belirlendi (p<0,005). 
Sonuç: Enterokok suşlarında antimikrobiyal direnç artmaktadır. Bu yüzden hem YDAD hem de vankomisin içeren direnç 
paternlerinin izlenmesi gereklidir.
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INTRODUCTION
Enterococci found in the normal flora of the gas-
trointestinal system have recently become one of 
the  major  nosocomial  pathogens. These  bacteria 
were isolated from the urinary tract infections, in-
tra-abdominal and pelvic infections as well as the 
causative  agents  of  endocarditis,  surgical  wound 
infections, bacteremia, neonatal sepsis and rarely 
of  meningitis.1,2 The  drawback  of  the  control  and 
treatment of enterococcal infections is their intrinsic 
resistance to various antibiotics, their capabilities to 
develop new resistance and to live in the external 
environment for a long time.
The cell wall inhibitors such as penicillin, am-
picillin, or vancomycin have been administered in 
combination  with  the  aminoglycosides  such  as 
streptomycin and gentamicin in the treatment of se-
rious infections caused by enterococci.3 A synergis-
tic effect between the cell wall synthesis inhibitors 
and aminoglycosides disappears in the presence of 
high-level resistance to aminoglycoside and causes 
difficulties in the treatment of severe enterococcal 
infections.4
In this study we attempted to determine anti-
biotic sensitivity rates of vancomycin-sensitive en-
terococci (VSE) recovered from a variety of clinical 
material in Haydarpaşa Numune Training and Re-
search Hospital, Istanbul, Turkey and antibiotic sen-
sitivity  rates  in  vancomycin-resistant enterococci 
(VRE) by the disk diffusion method and to identify 
minimum inhibitory concentration (MIC) values for 
vancomycin, teicoplanin and linezolid in VRE strains 
by means of E-test method and to compare a high-
level aminoglycoside resistance rates in VRE and 
VSE species.
METHODS
The study was performed in the laboratory of clinical 
microbiology of Haydarpaşa Numune Training and 
Research  Hospital  in  2008. The  study  was  com-
prised of 200 Enterococcus species recovered from 
clinical materials and rectal swab samples. Stuart’s 
transport medium was used in collecting rectal swab 
samples.  The  samples  were  cultivated  onto  bile 
esculin agar media containing 100 mg/ml azide and 
were incubated at 35 °C for 24 hours. Black-colored 
colonies grown in bile-esculin agar were evaluated 
in terms of enterococci. The clinical materials were 
seeded in appropriate media and were incubated at 
35 °C for 24 hours. The colonies suspected of en-
terococci were identified with Gram staining, cata-
lase, PYR and, bacterial growth in 6.5% NaCl and 
API 20 Strep (bioMerieux®, France).
The antimicrobial susceptibility tests were car-
ried out in accordance with Clinical and Laboratory 
Standards Institute (CLSI) criteria applying the Kir-
by-Bauer disk diffusion method by means of peni-
cillin,  ampicillin,  nitrofurantoin,  tetracycline,  cipro-
floxacin, vancomycin, and teicoplanin discs (Oxoid 
Ltd, Basingstoke, UK) in all enterococcal species.5 
Brain-heart infusion (BHI) agar containing 500 μg/
ml of gentamicin and BHI agar containing 2000 μg/
ml of streptomycin were used in an attempt to deter-
mine high-level gentamicin resistance (HLGR) and 
high-level streptomycin resistance (HLSR), respec-
tively. The BHI agar containing 6 μg/mL of vanco-
mycin was used to determine resistance to vanco-
mycin. The MIC values for vancomycin, teicoplanin 
and linezolid in VRE strains were evaluated by the 
vancomycin agar screen test in accordance with the 
CLSI recommendations for the E-test method (AB 
Biodisk®, Sweden).5
Beta-lactamase resistance was examined us-
ing nitrocefin disks. (Becton Dickinson®, USA). In 
our  study,  standard  Enterococcus faecalis  ATCC 
29212 strain was used as the control. Chi-square 
test was used for statistical analysis. The results 
were evaluated at the significance level of p<0.05.
RESULTS
The  study  was  comprised  of  100  VRE  and  100 
VSE strains. All of VSE strains were isolated from 
the clinical materials. Of the VRE strains, 57 were 
collected from rectal swabs, 43 were collected from 
clinical  materials  respectively  (Table  1).  All  VRE 
strains were defined as Enterococcus faecium and 
had high-level vancomycin resistance (MIC, >256 
µg/ml). When the minimal inhibitory concentration 
of teicoplanin was examined in VRE strains, Five 
of 100 VRE strains were found to be moderately 
susceptible (MIC, =16 µg/ml) and 95 strains were 
determined to be resistant (MIC, >32 µg/ml) against 
teicoplanin. One of the VRE strains that had high-
level resistance to vancomycin and teicoplanin was 
linezolid-resistant  (MIC,  =12  µg/ml)  and  another 
was moderately susceptible (MIC, =4 µg/ml) the re-
mainders were evaluated as susceptible (MIC, <2 
µg/ml) to linezolid. Penicillin, ampicillin, tetracycline, 
teicoplanin, and nitrofurantoin resistance was found 
to be 100% and erythromycin and ciprofloxacin re-
sistance was 99% and linezolid resistance was 2% 
in VRE strains using the disk diffusion method.
Of the 100 VSE strains, 51 were obtained from 
urine specimens. When VSE strains were examined 
on the basis of the isolation sites, most of E. faecalis 
were isolated from the urine, wound and bile culture 
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most of E. faecium were isolated from blood culture 
samples (56%). Of the 100 VSE strains, E. faecalis 
was responsible for 53%, E. faecium 42%, Entero-
coccus durans 3%, and Enterococcus avium 2%. 
Penicillin resistance was 33%, ampicillin resistance 
was 24%, erythromycin resistance was 92%, tet-
racycline resistance was 78%, ciprofloxacin resis-
tance was 71%, nitrofurantoin resistance was 27% 
in VSE strains by the disk-diffusion method. 
Table 1. Distribution of enterococcus strains to isolation 
sites (n=200)
Rectal
 swap
Blood Urine
Other
 samples
Vancomycin-resistant
 enterococci (n=100)
57 25 13 5
Vancomycin-sensitive
 enterococci (n=100)
- 25 51 24
Gentamycin  and  streptomycin  resistance  in 
E. faecium and E. faecalis was established to be 
20% and 14% in VSE strains respectively (Table 2). 
When VRE was compared to VSE, the rate of HLSR 
was detected to be 89% in VRE, while it was 48% in 
VSE; the rate of HLGR was noted to be 83% in VRE 
and it was 42% in VSE. The association of HLGR 
with HLSR namely high-level aminoglycoside resis-
tance (HLAR) was 78% in VRE, and 36% in VSE 
strains  respectively.  HLAR  was  found  to  be  sig-
nificantly higher in VRE strains than those in VSE 
strains (p<0.005; Table 3).
Table 2. Distribution of high-level aminoglycoside resis-
tance (HLAR) among vancomycin-sensitive enterococci 
(n=100)
E. faecalis E. faecium E. avium E. durans
Gen R-Strep R 14 20 1 1
Gen S-Strep S 31 12 1 2
Gen R-Strep S 1 5 - -
Gen S-Strep R 7 5 - -
Gen R=gentamicin resistant; Strep R=streptomycin resis-
tant; Gen S=gentamicin sensitive; Strep S=streptomycin 
sensitive.
Table 3.  Comparison  of  high-level  aminoglycoside  re-
sistance (HLAR) between vancomycin resistant entero-
cocci (VRE) and vancomycin-sensitive enterococci (VSE) 
(n=200)
Variable VRE (n=100) VSE (n=100) p-value
Gen R-Strep R 78 36 <0.0001
Gen S-Strep S 6 46 <0.0001
Gen R-Strep S 5 6 1.0
Gen S-Strep R 11 12 1.0
Gen R=gentamicin resistant; Strep R=streptomycin resistant; 
Gen S=gentamicin sensitive; Strep S=streptomycin sensitive.
DISCUSSION
Ampicillin resistance in enterococci may be caused 
either  by  change  in  penicillin-binding  proteins  or 
rarely by production of a beta-lactamase enzyme. 
VRE have multiple antibiotic resistance comprising 
the aminoglycosides (including high level of resis-
tance) and ampicillin.6 The penicillin and ampicillin 
resistant VSE strains were determined to be 33%, 
23%  and  ampicillin  resistant  VRE  strains  to  be 
100% by disk diffusion method in our study. In two 
different studies penicillin resistance was noted to 
be 25.7% and 28.8% and ampicillin resistance was 
noted to be 18.6% and 28.8%.3,7 The other study 
on VRE strains ampicillin resistance consistent with 
our study.8
Glycopeptide resistance in enterococci is one 
of the most important challenges. VRE takes place 
among the important nosocomial pathogens, in that 
the treatment options are limited, it easily spreads 
in  the  hospital  setting  and  it  is  likely  to  transfer 
vancomycin  resistance  to  other  pathogens.  VRE 
is known to spread in the hospital setting through 
contaminated hands and surfaces. Centers for Dis-
ease Control and Prevention (CDC) suggests that 
aggressive  infection  control  be  implemented  and 
that hospital staff conform to the isolation precau-
tions in order to control and prevent VRE infection.9 
VRE was first reported in 1998 in our country, fol-
lowed by a multi-hospital VRE outbreaks.10-12 The 
first VRE strain was isolated in our hospital in 2005. 
After  the  establishment  of  VRE,  contact  isolation 
was implemented for the patients and rectal swab 
samples were collected from clinics where VRE was 
detected particularly in the intensive care unit and 
screenings were performed.13
E. faecalis (80-90%) and E. faecium (10-15%) 
in enterococci were the species that were clinically 
isolated  highest.3  Although  E. faecalis was  fre-
quently isolated as infectious agents, vancomycin 
resistance was detected at a higher rate in E. fae-
cium.14,15 We detected all VRE strains as E. faecium 
and E. faecalis was the most in VSE strains. 
HLAR is caused by the secretions of various 
aminoglycoside-modifying  enzymes.16  The  rate 
of HLAR in VRE was determined to be higher as 
compared to that of VSE strains. In the study by 
Mihajlovic et al.17 on VRE strains HLGR was iden-
tified to be 87.6%, and HLSR to be 95.2%, while 
in the study by Yildirim et al.18 HLSR and HLGR in 
VSE strains were determined to be 19.8%, 9.9%, 
respectively. The rate of HLAR in VRE strains was 
significantly higher than VSE strains in our study. 
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HLAR poses difficulty in the treatment of especially 
severe infections. 
HLAR in E. faecium strains appears to be high-
er than that of E. faecalis. In the study by Mendiratta 
et al.16 of 150 of enterococcal species, 69 (49%) had 
high-level resistance to gentamicin and/or strepto-
mycin. In their study, HLGR (95.5%) was significant-
ly higher in E. faecium species as compared with 
E. faecalis species (37.5%). A study performed in 
Turkey found that 52% of E. faecium were HLGR 
and 74% were HLSR and 20% of E. faecalis spe-
cies were HLGR, and 31% were HLSR.15 In that 
study no vancomycin resistance was also found in 
E. faecium and E. faecalis species. We detected E. 
faecium to be 57.7% in VSE strains where a HLAR 
was detected. Our results were regarded as com-
patible with other studies. 
Treatment choice in VRE is limited. Linezolid, a 
ribosomal protein synthesis inhibitor, was approved 
by FDA in the USA for use in some VRE infections.19 
However, enterococci may be resistant to linezolid, 
which reduces the treatment options. In our study, 
one of the VRE species was linezolid-resistant and, 
the other was identified as moderately sensitive. In 
our hospital, following isolation of linezolid-resistant 
enterococci not only were training programs on in-
fection control measures intensified but also poli-
cies regarding antibiotic use were revised. It is con-
sidered that, although there has been no linezolid 
resistance after taking these measures, precaution 
for infection control is necessary to ensure continu-
ity.
The limitation of our study is that no molecu-
lar methods have been used. It is of significance 
to identify the type of vancomycin resistance to en-
terococci in treatment. The strains containing vanA 
and  vanB  genes  carry  a  high  level  of  resistance 
to  vancomycin,  while  those  carrying  VanC  gene 
show a low level of resistance to vancomycin. The 
strains with vanA gene are resistant to teicoplanin 
as well as vancomycin while those with vanB gene 
are susceptible to teicoplanin. It is likely to identify 
microorganisms by molecular methods and to de-
termine the relationship between them. Thus, mo-
lecular methods yield results earlier as compared 
with routine methods, allowing isolation measures 
in colonized patients without delay. However, mo-
lecular  techniques  are  associated  with  increased 
cost, limiting its use.
Being familiar with the characteristics of resis-
tance  in  enterococci,  the  accurate  determination 
of the results of antibiotic susceptibility will provide 
the appropriate treatment of infections produced by 
these pathogens. VRE continues to pose a threat to 
our hospital. A higher resistance rate to other antibi-
otics in VRE strains, particularly to aminoglycosides 
is also troublesome. Limited treatment options for 
serious infections caused by resistant enterococci 
make it necessary to intensify infection control pro-
cedures and a follow-up of resistance.
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